MIAMI, Sept. 9, 2024
MIAMI, Sept. 9, 2024 /PRNewswire/ -- The FDA has granted approval on Illumina's TruSight Oncology Comprehensive Assay, marking a transformative milestone in cancer diagnostics. This innovative in vitro diagnostic (IVD) kit is the first of its kind, offering distributable comprehensive genomic profiling (CGP) with pan-cancer companion diagnostic claims. PreCheck Health Services is excited to introduce this test under the name SolidTumorCheck+, marking the beginning of a new phase in precision oncology and patient care.
Advertisement
With the ability to process the TruSight Oncology Comprehensive assay, PreCheck Health Services can now provide patients with enhanced access to cutting-edge cancer treatments. This advancement enables rapid and detailed genomic profiling, helping clinicians deliver more targeted and personalized treatment strategies.
Advertisement
A Monumental Advancement for Cancer Diagnostics
The FDA's approval of the TruSight Oncology Comprehensive test marks a significant leap forward for both medical professionals and patients. The test analyzes over 500 gene biomarkers, supporting CGP across multiple cancer types. This detailed molecular profiling provides clinicians with actionable insights to recommend targeted therapeutic options, supported by two companion diagnostic claims.
What is TruSight Oncology Comprehensive?
TruSight Oncology Comprehensive is the first FDA-approved diagnostic kit designed to elevate cancer genomics. By profiling over 500 gene biomarkers, it aids in detecting cancer-driving genetic alterations across a variety of tumor types. Its standout feature is the pan-cancer companion diagnostic capability, which enables personalized therapy recommendations based on a patient's specific genomic profile.
Key Features and Benefits of SolidTumorCheck+
Advantages for Clinical Labs:
Frequently Asked Questions
Conclusion
The FDA approval of TruSight Oncology Comprehensive is a defining moment in the world of cancer diagnostics and precision medicine. By bringing this advanced assay to their patients, PreCheck Health Services is driving progress in cancer care, allowing more patients to access personalized treatment closer to home. With its comprehensive capabilities and pan-cancer companion diagnostic claims, SolidTumorCheck+ is set to revolutionize cancer treatment, providing new hope for improved outcomes.
For PreCheck Health Services, offering this cutting-edge test reinforces its position in the rapidly evolving field of cancer genomics. By processing the FDA-approved SolidTumorCheck+, they not only contribute to vital research but also offer life-changing resources to patients in their communities.
Contact InformationPreCheck Health Services, Inc.100 Biscayne Blvd, Suite 1611, Miami, FL [email protected] +1 (214) 680-5000
View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-illuminas-trusight-oncology-comprehensive-assay-now-offered-by-precheck-health-services-as-solidtumorcheck--a-breakthrough-in-precision-oncology-302241197.html
SOURCE PreCheck Health Services, Inc.
